15-Hydroxyprostaglandin Dehydrogenase in Osteoarthritis and Ankylosing Spondylitis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
To evaluate serum and synovial fluid 15-PGDH levels in patients with osteoarthritis and ankylosing spondylitis and determine their associations with clinical and musculoskeletal ultrasound features.
To compare 15-PGDH concentrations among patients with knee osteoarthritis, and ankylosing spondylitis with knee effusion
To evaluate whether serum 15-PGDH reflects intra-articular 15-PGDH concentrations.
Analysis the level of 15-PGDH in relation to disease activity and severity of both diseases.
Eligibility criteria
Qualifiers
Inclusion criteria
Adults aged 18 years or older. AxSpA group Patients diagnosed as ankylosing spondylitis according to ASAS criteria . R OA group
Adults with osteoarthritis Diagnosed according to the American College of Rheumatology classification criteria.[8]R ACR Clinical classification criteria for Osteoarthritis of the hip ACR Clinical classification criteria for Osteoarthritis of the knee ACR Clinical classification criteria for Osteoarthritis of the hand Control group Age- and sex-matched healthy controls.
Disqualifiers
• Other inflammatory arthritides such as psoriatic arthritis, gout, or SLE-related arthritis.
Septic arthritis or suspected joint infection.
Recent intra-articular steroid injection if it may influence biomarker results.
Any major systemic illness likely to affect biomarker measurement or ultrasound interpretation.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
51 Participants
are grouped into 1 trial groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov